WuXi AppTec Adds 800 Tonnes of API Capacity in Changzhou: RMB 10.1B Investment, 630 Mu Site, 2026 Capex of RMB 7.5-8.5B

A Morgan Stanley note dated 15 October disclosed that WuXi AppTec plans to invest RMB 10.1B to expand WuXi STA's Changzhou site, adding 800 tonnes of API capacity on about 420,000 sqm (630 mu), focused on technical services and process development across six therapeutic areas. Combined with 2026 targets to lift small-molecule reactor capacity from 4,000 to 5,000 cbm and solid-phase peptide synthesis from 100,000 to 130,000 L, the expansion pace now exceeds the original plan and serves as a leading indicator for 2027.

In a note dated 15 October, Morgan Stanley maintained an Overweight rating and HK$207.40 target price on WuXi AppTec (02359.HK), with the core message a capacity plan that the market has not fully priced: the company intends to invest RMB 10.1B to expand the Changzhou site of its subsidiary WuXi STA, adding an estimated 800 tonnes of active pharmaceutical ingredient capacity in phases over the coming years. The new site covers about 420,000 square metres, roughly 630 mu.

Three capacity targets revised at once

Placing this investment against the company's stated 2026 capacity targets shows the change in pace. The company had planned to lift small-molecule reactor capacity from 4,000 to 5,000 cubic metres (+25%) and solid-phase peptide synthesis (SPPS) capacity from 100,000 to 130,000 litres (+30%) within 2026, with capital expenditure guidance of RMB 7.5-8.5B, part of it already earmarked for the new Changzhou base. Morgan Stanley states plainly that the 800-tonne expansion 'exceeds the original target', evidence that group capacity expansion has accelerated.

The characterisation of the project matters as much as the tonnage. The note says the expansion will focus on technical services and process development, specifically addressing stability and toxicology testing needs for branded drugs. That is not simply piling on volume: it moves high-value, high-stickiness service capability into an API site. For clients it means process continuity and data traceability from preclinical through commercialisation inside one campus; for the company it puts development service revenue and commercial manufacturing revenue on the same balance sheet.

Six therapeutic areas and the weight of peptides

The new base will serve six therapeutic areas: diabetes, oncology, cardiovascular, antivirals, autoimmune disease and infectious disease. Peptide programmes within that mix span oncology, diabetes, infectious disease and cardiovascular — consistent with the expansion of the TIDES business, which generated RMB 7.26B in H1 2026, up 44.3% and equal to 25.1% of revenue, with roughly 45% growth expected for the full year. As GLP-1 peptides move from rare metabolic indications to large-scale chronic disease, API demand shifts from kilograms to tonnes, which is precisely why 800 tonnes of API and 130,000 litres of SPPS have to advance together.

Q3 results on 26 October: consensus points to re-acceleration

The current fundamentals behind the investment: H1 2026 revenue of RMB 28.897B (+38.93%), non-GAAP attributable net profit of RMB 10.572B (+89.39%) and gross margin of 53.91% versus about 44.4% a year earlier; continuing-operations backlog of RMB 66.43B (+25.2%); and full-year revenue guidance raised from RMB 51.3-53.0B to RMB 58.5-60.5B. Consensus for the 26 October report is revenue of about RMB 15.294B (+26.8% YoY) and net profit of about RMB 5.401B (+53.7%); Zheshang Securities is more optimistic, modelling Q3 revenue growth of 30-40% and adjusted net profit growth of 56-76%, with nine-month revenue up 36-39%.

One accounting trap needs flagging before reading that report: on 27 August the company reduced its stake in WuXi XDC, generating an estimated RMB 3.143B of pre-tax investment income (about RMB 2.67B after tax) that will flow through Q3 attributable net profit. Attributable and non-GAAP/adjusted net profit will therefore diverge sharply, and cross-company comparisons must use a single basis or they will overstate the operational improvement.

Editor's view: the small-molecule 'overcapacity' thesis is retiring

The prevailing view on Chinese small-molecule CDMOs in 2024-2025 was overcapacity and price war. WuXi AppTec's RMB 10.1B expansion is a direct rebuttal, but not by arguing that total capacity is short — it is arguing that premium capacity is short. Commodity reactors are indeed oversupplied; what remains scarce is capacity that can handle branded-drug stability and toxicology batches, run high-potency chemistry and solid-phase peptide synthesis, and carry a programme from process development to commercial scale on one campus. That matches feedback from CPHI Milan 2026, where customers compared Asia against the US and Europe rather than China against China, with price gaps of several multiples, and competition concentrated on premium lines that can hold a schedule.

The second observation is depreciation timing. The RMB 10.1B will be spent in phases over several years, so 800 tonnes of capacity and ramp costs will not hit the P&L at once, but 2027-2028 will bring concentrated depreciation. Morgan Stanley calls the expansion a positive leading indicator for 2027 on the logic that capacity precedes orders and orders precede revenue; conversely, if global biopharma funding cools in 2027, that capacity turns from leading indicator into margin drag. It is also why the company holds 2026 capex at RMB 7.5-8.5B and reserves only part of it for Changzhou instead of building everything at once.

The third observation is the symmetry of competition. In the same week, Samsung Biologics committed a KRW 3T rights offering to fund the PolyPeptide acquisition and a 1,385,000 L antibody capacity plan, while Lonza raised its mid-term margin ambition to the high thirties and kept capex at a mid-to-high teens percentage of sales — all three global leaders chose to keep investing in capacity in 2026. What differs is where: Samsung in antibodies and peptides, Lonza in complex biologics and ADC platforms, WuXi AppTec in small-molecule API and peptides. All three bets face a demand test around 2028, and which one proves right will define the next cycle more than any single quarter.